Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ziprasidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 13/20 | 0.96 |
| ▸ | DRD2 known ✓ | P14416 | 11/20 | 0.96 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 8/20 | 0.96 |
| ▸ | HTR7 | P34969 | 3/20 | 0.96 |
| ▸ | HTR6 | P50406 | 2/20 | 0.96 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.96 |
| ▸ | HTR3B | O95264 | 1/20 | 0.96 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.96 |
| ▸ | PGR | P06401 | 1/20 | 0.96 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.96 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.96 |
| ▸ | GOT1 | P17174 | 1/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ziprasidone SCHEMBL930539 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL1164202 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL122875 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL29594402 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL10324884 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL6061373 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL2978306 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL4914143 | 0.99 | HTR2A (0.98) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL30354044 | 0.99 | HTR2A (0.98) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL374870 | 0.99 | HTR2A (0.98) | KCNH2MTORRAB9AHTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777037-B2 | Ziprasidone process | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-08-17 | — | — | US | claimed |
| US-20090163513-A1 | PROCESS FOR ZIPRASIDONE USING NOVEL INTERMEDIATES | HETERO DRUGS LIMITED (IN) | 2009-06-25 | — | — | US | claimed |
| EP-1841764-A1 | PROCESS FOR ZIPRASIDONE USING NOVEL INTERMEDIATES | Hetero Drugs Limited (IN) | 2007-10-10 | — | — | EP | claimed |
| WO-2006080025-A1 | PROCESS FOR ZIPRASIDONE USING NOVEL INTERMEDIATES | HETERO DRUGS LIMITED (IN) | 2006-08-03 | — | — | WO | claimed |
| WO-2010073255-A1 | PROCESS FOR PREPARING ZIPRASIDONE | CADILA HEALTHCARE LIMITED (IN) | 2010-07-01 | — | — | WO | disclosed |
| US-20100081668-A1 | POLYMORPHS OF 5--6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | RICHTER GEDEON NYRT. (HU) | 2010-04-01 | — | — | US | disclosed |
| EP-2084156-A1 | POLYMORPHS OF 5-{2-[4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL]-ETHYL}-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | Richter Gedeon NYRT (HU) | 2009-08-05 | — | — | EP | disclosed |
| US-20090163513-A1 | PROCESS FOR ZIPRASIDONE USING NOVEL INTERMEDIATES | HETERO DRUGS LIMITED (IN) | 2009-06-25 | — | — | US | disclosed |
| US-20090047354-A1 | PROCESS FOR THE PREPARATION OF 5-(2-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL) ETHYL)-6-CHLORO-1, 3-DIHYDRO-2H-INDOL-2-ONE HYDROCHLORIDE (ZIPRASIDONE HYDROCHLORIDE) AND ITS INTERMEDIATE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-02-19 | — | — | US | disclosed |
| EP-1975169-A1 | Process for the preparation of ziprasidone | INKE, S.A. (ES) | 2008-10-01 | — | — | EP | disclosed |
| US-20080214816-A1 | Process for Preparing Ziprasidone | SANDEN CORPORATION (JP) | 2008-09-04 | — | — | US | disclosed |
| WO-2008062244-A1 | POLYMORPHS OF 5-{2-[4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL]-ETHYL}-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | RICHTER GEDEON NYRT. (HU) | 2008-05-29 | — | — | WO | disclosed |
| WO-2006080025-A1 | PROCESS FOR ZIPRASIDONE USING NOVEL INTERMEDIATES | HETERO DRUGS LIMITED (IN) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006034964-A1 | PROCESS FOR PREPARING ZIPRASIDONE | MEDICHEM, S.A. (ES) | 2006-04-06 | — | — | WO | disclosed |
| US-20050277651-A1 | Preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride (ziprasidone hydrochloride) | APOTEX PHARMACHEM INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005108395-A1 | ZIPRASIDONE HYDROCHLORIDE POLYMORPH AND PROCESS FOR ITS PREPARATION | DIPHARMA S.P.A. (IT) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108395-A1 | ZIPRASIDONE HYDROCHLORIDE POLYMORPH AND PROCESS FOR ITS PREPARATION | DIPHARMA S.P.A. (IT) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005100348-A1 | AMORPHOUS ZIPRASIDONE HYDROCHLORIDE | LUPIN LIMITED (IN) | 2005-10-27 | — | — | WO | disclosed |
| US-20050049295-A1 | Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate | DR. REDDY'S LABORATORIES LIMITED | 2005-03-03 | — | — | US | disclosed |
| EP-0904273-B1 | MESYLATE TRIHYDRATE SALT OF 5-(2-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL)ETHYL)-6-CHLORO-1,3-DIHYDRO-2(1H)-INDOL-2-ONE (=ZIPRASIDONE), ITS PREPARATION AND ITS USE AS DOPAMINE D2 ANTAGONIST | PFIZER (US) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081668-A1 | POLYMORPHS OF 5--6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | TPH1, TPH2, HTR1A | HTR2A 28/4885DRD2 32/4885HTR2C 17/4885 |
| US-20050277651-A1 | Preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride (ziprasidone hydrochloride) | HDAC3, CA2, HDAC2 | HTR2A 226/4885DRD2 652/4885HTR2C 247/4885 |
| US-20050049295-A1 | Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate | OPRK1, TPH1, TPH2 | HTR2A 29/4885DRD2 46/4885HTR2C 17/4885 |
| US-20090163513-A1 | PROCESS FOR ZIPRASIDONE USING NOVEL INTERMEDIATES | SIGMAR1, SI, SLC39A11 | HTR2A 31/4885DRD2 66/4885HTR2C 27/4885 |
| US-20090047354-A1 | PROCESS FOR THE PREPARATION OF 5-(2-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL) ETHYL)-6-CHLORO-1, 3-DIHYDRO-2H-INDOL-2-ONE HYDROCHLORIDE (ZIPRASIDONE HYDROCHLORIDE) AND ITS INTERMEDIATE | OPRK1, OPRD1, TPH1 | HTR2A 28/4885DRD2 41/4885HTR2C 16/4885 |
| US-20080214816-A1 | Process for Preparing Ziprasidone | SLC39A3, SLC30A6, SIGMAR1 | HTR2A 487/4885DRD2 630/4885HTR2C 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.